89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors

Albert J. Chang; Ravindra DeSilva; Sandeep Jain; Kimberley Lears; Buck Rogers; Suzanne Lapi

doi:10.3390/ph5010079

⁸⁹Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors

Albert J. Chang, Ravindra DeSilva, Sandeep Jain, Kimberley Lears, Buck Rogers, Suzanne Lapi

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Abstract

The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile ⁸⁹Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the ⁸⁹Zr-trastuzumab produced by this simpler method.

Original language	English
Pages (from-to)	79-93
Number of pages	15
Journal	Pharmaceuticals
Volume	5
Issue number	1
DOIs	https://doi.org/10.3390/ph5010079
State	Published - Jan 5 2012

Keywords

HER2
ImmunoPET
PET

Access to Document

10.3390/ph5010079

Cite this

@article{a33a0e1b20334537824bc0e9bda38f96,

title = "89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors",

abstract = "The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.",

keywords = "HER2, ImmunoPET, PET",

author = "Chang, {Albert J.} and Ravindra DeSilva and Sandeep Jain and Kimberley Lears and Buck Rogers and Suzanne Lapi",

year = "2012",

month = jan,

day = "5",

doi = "10.3390/ph5010079",

language = "English",

volume = "5",

pages = "79--93",

journal = "Pharmaceuticals",

issn = "1424-8247",

number = "1",

}

TY - JOUR

T1 - 89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors

AU - Chang, Albert J.

AU - DeSilva, Ravindra

AU - Jain, Sandeep

AU - Lears, Kimberley

AU - Rogers, Buck

AU - Lapi, Suzanne

PY - 2012/1/5

Y1 - 2012/1/5

N2 - The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.

AB - The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.

KW - HER2

KW - ImmunoPET

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84856261443&partnerID=8YFLogxK

U2 - 10.3390/ph5010079

DO - 10.3390/ph5010079

M3 - Article

C2 - 24288044

AN - SCOPUS:84856261443

SN - 1424-8247

VL - 5

SP - 79

EP - 93

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 1

ER -

⁸⁹Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this